Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice

Paul J. Hampel, Wei D Ding, Timothy G. Call, Kari G. Rabe, Saad Kenderian, Thomas Elmer Witzig, Eli Muchtar, Jose F. Leis, Asher A Chanan Khan, Amber B. Koehler, Amie L. Fonder, Susan M. Schwager, Susan L Slager, Tait D. Shanafelt, Neil Elliot Kay, Sameer A Parikh

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

We identified all patients with chronic lymphocytic leukemia at Mayo Clinic treated with ibrutinib outside the context of a clinical trial; timing and reasons for discontinuation were ascertained, as were symptoms, exam and radiographic findings, and laboratory changes following discontinuation. Of 202 patients who received ibrutinib, 52 discontinued therapy (estimated 1- and 2-year risk of discontinuation 18% and 28%, respectively). The most common reasons for discontinuation were toxicity (56%) and progression of disease (32%, including Richter’s transformation in 15%). Rapid progression of disease within 4 weeks after discontinuation was observed in 9/36 (25%) patients with adequate records for review, mostly in those stopping ibrutinib for disease progression (n = 8) rather than toxicity (n = 1). This was evident by sudden worsening of disease-related symptoms (n = 9), exam/radiographic changes (n = 7), and laboratory changes (n = 8). An estimated one in every three patients discontinued ibrutinib by 2 years, with 25% developing rapid disease progression afterwards.

Original languageEnglish (US)
JournalLeukemia and Lymphoma
DOIs
StatePublished - Jan 1 2019

Fingerprint

B-Cell Chronic Lymphocytic Leukemia
Disease Progression
Clinical Trials
PCI 32765
Therapeutics

Keywords

  • Chronic lymphocytic leukemia (CLL)
  • discontinuation
  • ibrutinib
  • progression

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice. / Hampel, Paul J.; Ding, Wei D; Call, Timothy G.; Rabe, Kari G.; Kenderian, Saad; Witzig, Thomas Elmer; Muchtar, Eli; Leis, Jose F.; Chanan Khan, Asher A; Koehler, Amber B.; Fonder, Amie L.; Schwager, Susan M.; Slager, Susan L; Shanafelt, Tait D.; Kay, Neil Elliot; Parikh, Sameer A.

In: Leukemia and Lymphoma, 01.01.2019.

Research output: Contribution to journalArticle

@article{289d40f0c4d942f29258a958bfb52178,
title = "Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice",
abstract = "We identified all patients with chronic lymphocytic leukemia at Mayo Clinic treated with ibrutinib outside the context of a clinical trial; timing and reasons for discontinuation were ascertained, as were symptoms, exam and radiographic findings, and laboratory changes following discontinuation. Of 202 patients who received ibrutinib, 52 discontinued therapy (estimated 1- and 2-year risk of discontinuation 18{\%} and 28{\%}, respectively). The most common reasons for discontinuation were toxicity (56{\%}) and progression of disease (32{\%}, including Richter’s transformation in 15{\%}). Rapid progression of disease within 4 weeks after discontinuation was observed in 9/36 (25{\%}) patients with adequate records for review, mostly in those stopping ibrutinib for disease progression (n = 8) rather than toxicity (n = 1). This was evident by sudden worsening of disease-related symptoms (n = 9), exam/radiographic changes (n = 7), and laboratory changes (n = 8). An estimated one in every three patients discontinued ibrutinib by 2 years, with 25{\%} developing rapid disease progression afterwards.",
keywords = "Chronic lymphocytic leukemia (CLL), discontinuation, ibrutinib, progression",
author = "Hampel, {Paul J.} and Ding, {Wei D} and Call, {Timothy G.} and Rabe, {Kari G.} and Saad Kenderian and Witzig, {Thomas Elmer} and Eli Muchtar and Leis, {Jose F.} and {Chanan Khan}, {Asher A} and Koehler, {Amber B.} and Fonder, {Amie L.} and Schwager, {Susan M.} and Slager, {Susan L} and Shanafelt, {Tait D.} and Kay, {Neil Elliot} and Parikh, {Sameer A}",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/10428194.2019.1602268",
language = "English (US)",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Rapid disease progression following discontinuation of ibrutinib in patients with chronic lymphocytic leukemia treated in routine clinical practice

AU - Hampel, Paul J.

AU - Ding, Wei D

AU - Call, Timothy G.

AU - Rabe, Kari G.

AU - Kenderian, Saad

AU - Witzig, Thomas Elmer

AU - Muchtar, Eli

AU - Leis, Jose F.

AU - Chanan Khan, Asher A

AU - Koehler, Amber B.

AU - Fonder, Amie L.

AU - Schwager, Susan M.

AU - Slager, Susan L

AU - Shanafelt, Tait D.

AU - Kay, Neil Elliot

AU - Parikh, Sameer A

PY - 2019/1/1

Y1 - 2019/1/1

N2 - We identified all patients with chronic lymphocytic leukemia at Mayo Clinic treated with ibrutinib outside the context of a clinical trial; timing and reasons for discontinuation were ascertained, as were symptoms, exam and radiographic findings, and laboratory changes following discontinuation. Of 202 patients who received ibrutinib, 52 discontinued therapy (estimated 1- and 2-year risk of discontinuation 18% and 28%, respectively). The most common reasons for discontinuation were toxicity (56%) and progression of disease (32%, including Richter’s transformation in 15%). Rapid progression of disease within 4 weeks after discontinuation was observed in 9/36 (25%) patients with adequate records for review, mostly in those stopping ibrutinib for disease progression (n = 8) rather than toxicity (n = 1). This was evident by sudden worsening of disease-related symptoms (n = 9), exam/radiographic changes (n = 7), and laboratory changes (n = 8). An estimated one in every three patients discontinued ibrutinib by 2 years, with 25% developing rapid disease progression afterwards.

AB - We identified all patients with chronic lymphocytic leukemia at Mayo Clinic treated with ibrutinib outside the context of a clinical trial; timing and reasons for discontinuation were ascertained, as were symptoms, exam and radiographic findings, and laboratory changes following discontinuation. Of 202 patients who received ibrutinib, 52 discontinued therapy (estimated 1- and 2-year risk of discontinuation 18% and 28%, respectively). The most common reasons for discontinuation were toxicity (56%) and progression of disease (32%, including Richter’s transformation in 15%). Rapid progression of disease within 4 weeks after discontinuation was observed in 9/36 (25%) patients with adequate records for review, mostly in those stopping ibrutinib for disease progression (n = 8) rather than toxicity (n = 1). This was evident by sudden worsening of disease-related symptoms (n = 9), exam/radiographic changes (n = 7), and laboratory changes (n = 8). An estimated one in every three patients discontinued ibrutinib by 2 years, with 25% developing rapid disease progression afterwards.

KW - Chronic lymphocytic leukemia (CLL)

KW - discontinuation

KW - ibrutinib

KW - progression

UR - http://www.scopus.com/inward/record.url?scp=85064767026&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85064767026&partnerID=8YFLogxK

U2 - 10.1080/10428194.2019.1602268

DO - 10.1080/10428194.2019.1602268

M3 - Article

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -